Cubresa

04/13/2026

We are proud to announce that Cubresa Inc. has signed a Letter of Intent (LOI) with The University of Edinburgh. This LOI is the first step towards a Collaboration Agreement focused on the development of a Pre-Clinical Therapeutic Road Map for Scaling Neurodegenerative Disease Interventions.

Areas of interest include:
- Precision Validation: Utilizing advanced molecular imaging to verify therapeutic efficacy earlier in the development cycle.

- Scalable Frameworks: Creating standardized protocols that allow promising interventions to move toward clinical trials with greater speed and reliability.

- Global Impact: Addressing the urgent need for scalable treatments for Alzheimer’s, Parkinson’s, and other neurodegenerative conditions.

Cubresa is incredibly proud to collaborate with the University of Edinburgh - and to push the boundaries of what’s possible in brain health!

03/11/2026

Cubresa Inc. is pleased to announce the signing of a Master Research Agreement (MRA) with Lawson Health Research Institute.

This agreement is an expansion of a 10-year research partnership with Lawson and marks a new era of collaboration in brain-focused pre-clinical and clinical research. Future projects will focus on advanced BrainPET imaging, streamlining the path from pre-clinical research discoveries into clinical environments where they can impact patient lives.

We are incredibly proud of what we have achieved together over the last decade and look forward to many more years of innovation and collaborative success with the Lawson team!

01/13/2026

Cubresa Files First FDA 510(k) Application

Cubresa Inc. is pleased to announce the company has submitted the Cubresa BrainPET™ 510(k) Premarket Notification to the Food and Drug Administration (FDA)

This submission marks a pivotal step in our company’s mission to bring world-class brain imaging technology into clinical settings,” remarked James Schellenberg, Cubresa’s Founder and CEO, “by seeking FDA clearance for our BrainPET technology, we are moving one step closer to providing clinicians with high performing, cost-effective, simultaneous PET/MRI imaging to assist in the diagnosis and monitoring of a broad spectrum of brain diseases.”

A huge thank you to our incredible team, partners, and investors who help Cubresa reach this milestone.



Forward Looking Statements
This release contains certain forward-looking statements regarding Cubresa's 510(k) premarket notification to the FDA for the BrainPET™ System. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, and there can be no assurance that Cubresa will obtain 510(k) clearance from the FDA for the BrainPET™ System or as to the timing of any such clearance. Many of these risks and uncertainties are beyond the company's control, including without limitation, risks relating to regulatory clearance and market acceptance of the System.

09/20/2021

Cubresa is pleased to announce that it has entered into a Memorandum of Understanding with the University of California, Davis to identify and explore technical and application-focused research projects related to Alzheimer’s Disease and simultaneous PET/MRI imaging.

Please follow the link below to learn more.

https://lnkd.in/eaTS-z_e

03/04/2021

Cubresa would like to congratulate Lawson Health Research Institute on being awarded funding through the Canadian Foundation for Innovation (CFI). Cubresa is proud to partner with Lawson, the first research centre that will install the Cubresa BrainPET system for clinical brain imaging research.

Lawson Health Research Institute has been awarded over $2 million in federal funding for a project focusing on two unique medical imaging systems designed to give unparalleled insight into brain function and disease.

02/02/2021

is proud to have the as the first installation site of its NuPET Bio imaging system

ow.ly/XvaN50DoBrm

The company is grateful for the support from and

The IWK has been named the site for the installation of a NuPET Bio imaging system, the first in the world specifically designed for infectious disease research in Bio Safety Lab 3 (BSL3) environme…

01/06/2021

Thank you Research Manitoba for supporting Cubresa's NuPET Bio project. We are proud to build tools that support scientists at the forefront of COVID-19 research!
https://researchmanitoba.ca/winnipeg-med-tech-companies-tackle-covid-19/…

Four months ago, Research Manitoba made a number of strategic investments in several local companies as part of the province’s bid to tackle the novel coronavirus that causes COVID-19.

10/31/2020

Cubresa is very pleased to announce that it has been selected by Innovative Solutions Canada to test our NuPET Bio system. This lightweight and portable PET imaging system is the world's first scanner designed for high containment facilities and will be used by scientists focused on SARS-CoV-2 research. We are excited to contribute to the global COVID-19 effort and support researchers looking to develop effective therapeutics to combat this virus.

The Government of Canada is committed to protecting the health and safety of all Canadians while ensuring economic resilience and contributing to the international response to COVID-19.

10/05/2020

Cubresa is looking forward to participating in WMIC 2020. Please visit us to learn more about our suite of NuPET imaging systems – especially our new BSL-3 compatible NuPET Bio scanner for imaging of infectious diseases.

08/12/2020

Cubresa is very pleased to be a recipient of the Research Manitoba COVID-19 Proof-of-Concept Grant!

08/07/2020

Please join the team from Cubresa at our booth at ISMRM 2020. Come by to learn more about Cubresa's range of PET inserts and stand alone systems.

08/05/2020

Cubresa is expanding!

  Careers Thank you for your interest in career opportunities at Cubresa. Cubresa is a world-leader in the design and development of PET insert technology. The company offers a dynamic and exciting work environment, enabling employees the opportunity to work at the forefront of the medical imaging ...